Study S001818

Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06182891
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: NONE
Status: COMPLETED
Enrollment: 300
Start: 2021-10-30
Primary completion: 2023-06-30
Lead sponsor: The Affiliated Hospital of Xuzhou Medical University
Conditions: Type 2 Diabetic Nephropathy
Interventions: DRUG:Dulaglutide Injection
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Evaluation of the urinary albumin-to-creatinine ratio [3,6 and 12 months after dulaglutide injection treatment]
Evaluation of the biomarkers of the epithelial-mesenchymal transition process [3,6 and 12 months after dulaglutide injection treatment]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0010237	Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Natale P, The Cochrane database of systematic reviews	2025	Systematic review	PMID 39963952 DOI	cites ClinicalTrials.gov:NCT06182891; registry reference DERIVED:39963952